Abstract
Management of hemangiomas by propranolol: Epidemiological, clinical and therapeutic aspects: retrospective study about 15 cases
Highlights
Angiomas are a heterogeneous group of vascular diseases including hemangiomas and malformations [1,2,3]
Lower frequencies have been reported: In Mali, GUINDO O et al reported on 4544 dermatological consultations 31 cases of angiomas during a study period from 19 July 2005 to 23 April 2009, ie 0.68% [9]; in Burkina Faso TRAORE FB et al in 2003 found 12 cases of angiomas among 14265 patients consulted during the study period from January 1, 1992 to December 31, 1996, a frequency of 0.08% [10].In our study the sex ratio was 1 man for 4 women
The 0-5 month age group was the most represented in our study (66.7%), with an average age of 5.8 months
Summary
Angiomas are a heterogeneous group of vascular diseases including hemangiomas and malformations [1,2,3]. Immature angioma or hemangioma is a benign vascular tumor of undetermined etiology following proliferation of endothelial and mesenchymal cells with formation of neo-vessels in the dermis [4,5]. They are the most common tumors of the child, with a prevalence of 10% and whose diagnosis is essentially clinical [4,5,6]. The purpose of this study was to determine the epidemiological and clinical aspects of angiomas, and to evaluate the outcome of the management of hemangioma by a betablocker, that is Propranolol
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
